UnknownPhase 2NCT02463825

A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Calgary
Principal Investigator
Lawrence Korngut, MD, FRCPC
University of Calgary and Alberta Health Services
Intervention
Pimozide 2 mg per day(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
20152021

Study locations (1)

Collaborators

Hotchkiss Brain Institute, University of Calgary

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02463825 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials